Skip to main content

Table 3 Difference in clinicopathological features due to body mass index categorized in TNBC

From: Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy

hba Body mass index (kg/m2) p value Body mass index (kg/m2 p value Body mass index (kg/m2) p value
≤ 18.5
(n = 17)
>  18.5
(n = 109)
≤ 25
(n = 98)
>  25
(n = 28)
≤ 30
(n = 123)
>  30
(n = 3)
Age (years old) 0.258
  ≤ 60 11 (64.7%) 78 (71.6%)   67 (68.4%) 22 (78.6%)   86 (69.9%) 3 (100.0%)
  > 60 6 (35.3%) 31 (28.4%) 0.564 31 (31.6%) 6 (21.4%) 0.296 37 (30.1%) 0 (0.0%)
Tumor size (mm) 0.433
  ≤ 20.0 4 (23.5%) 17 (15.6%)   18 (18.4%) 3 (10.7%)   20 (16.3%) 1 (33.3%)
  > 20.0 13 (76.5%) 92 (84.4%) 0.414 80 (81.6%) 25 (89.3%) 0.338 103 (83.7%) 2 (66.7%)
Skin infiltration 0.519
 Negative 13 (76.5%) 98 (89.9%)   88 (89.8%) 23 (82.1%)   108 (87.8%) 3 (100.0%)
 Positive 4 (23.5%) 11 (10.1%) 0.112 10 (10.2%) 5 (17.9%) 0.270 15 (12.2%) 0 (0.0%)
Lymph node status 0.952
 Negative 4 (23.5%) 36 (33.0%)   32 (32.7%) 8 (28.6%)   39 (31.7%) 1 (33.3%)
 Positive 13 (76.5%) 73 (67.0%) 0.434 66 (67.3%) 20 (71.4%) 0.682 84 (68.3%) 2 (66.7%)
Ki67 0.695
  ≤ 14% 2 (11.8%) 28 (25.7%)   24 (24.5%) 6 (21.4%)   29 (23.6%) 1 (33.3%)
  > 14% 15 (88.2%) 81 (74.3%) 0.210 74 (75.5%) 22 (78.6%) 0.737 94 (76.4%) 2 (66.7%)
Objective response rate 0.504
 Non-Responders 6 (35.3%) 10 (9.2%)   14 (14.3%) 2 (7.1%)   16 (13.0%) 0 (0.0%)
 Responders 11 (64.7%) 99 (90.8%) 0.003 84 (85.7%) 26 (92.9%) 0.317 107 (87.0%) 3 (100.0%)
Pathological response 0.777
 Non-pCR 9 (52.9%) 65 (59.6%)   58 (59.2%) 16 (57.1%)   72 (58.5%) 2 (66.7%)
 pCR 8 (47.1%) 44 (40.4%) 0.602 40 (40.8%) 12 (42.9%) 0.847 51 (41.5%) 1 (33.3%)
TILs 0.100
 Low 12 (70.6%) 47 (43.1%)   50 (51.0%) 9 (32.1%)   59 (48.0%) 0 (73.7%)
 High 5 (29.4%) 62 (56.9%) 0.035 48 (49.0%) 19 (67.9%) 0.077 64 (52.0%) 3 (100.0%)
  1. TNBC triple negative breast cancer, pCR pathological complete response, TILs tumor-infiltrating lymphocytes